esmolol has been researched along with procainamide in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Honerjäger, P; Schmidt, G | 1 |
| Biervliet, JD; Koster, RW; van Dantzig, JM | 1 |
| Drda, KD; Moses, JO; Robinson, DH; Schaaf, LJ; Vogel, GJ; Wulf, BG | 1 |
| Chen, SM; Chiang, FT; Kuo, CT; Lin, KH | 1 |
2 review(s) available for esmolol and procainamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[New anti-arrhythmia agents].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Humans; Phenethylamines; Procainamide; Propanolamines; Sotalol; Sulfonamides; Survival Rate; Tachycardia | 1992 |
7 other study(ies) available for esmolol and procainamide
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Treatment with esmolol of ventricular fibrillation unresponsive to lidocaine and procainamide.
Topics: Adrenergic beta-Antagonists; Adult; Humans; Lidocaine; Male; Procainamide; Propanolamines; Ventricular Fibrillation | 1991 |
Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride.
Topics: Aminophylline; Bretylium Tosylate; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Incompatibility; Drug Stability; Heparin; Hydrogen-Ion Concentration; Procainamide; Propanolamines; Spectrophotometry, Ultraviolet | 1990 |
Brugada syndrome without mutation of the cardiac sodium channel gene in a Taiwanese patient.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autonomic Nervous System; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Defibrillators, Implantable; Electrocardiography; Humans; Isoproterenol; Male; Middle Aged; Mutation; Procainamide; Propanolamines; Sodium Channels; Syndrome | 2000 |